Another study indicated that the tumor relapse was attributed to the dormancy of Lgr5+ cells and revealed that targeting Lgr5+ cells by inhibition of Wnt signaling (Wnt inhibitors, Lgk974) in combination with Vismodegib treatment resulted in regression of BCCs [183]. The gene discussed is LGR5; the disease is neoplasm.